Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Smith & Nephew    SN.   GB0009223206

SMITH & NEPHEW (SN.)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Smith & Nephew : Under pressure Smith & Nephew to focus on efficiency

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/03/2017 | 11:51am CEST

LONDON (Reuters) - Smith & Nephew (>> Smith & Nephew) said no major surgery is required for the artificial knee and hip maker to deliver shareholder value, even as it reported lacklustre sales that increase pressure on the company reportedly being stalked by activist investor Elliott.

LONDON (Reuters) - Smith & Nephew (>> Smith & Nephew) said no major surgery is required for the artificial knee and hip maker to deliver shareholder value, even as it reported lacklustre sales that increase pressure on the company reportedly being stalked by activist investor Elliott.

Two reports last month said that Paul Singer's U.S. hedge fund had taken a stake in Smith & Nephew, reigniting perennial speculation that it could be acquired by a U.S. rival such as Stryker (>> Stryker Corporation) or be broken up.

But Chief Executive Olivier Bohuon, whose plan to retire by the end of 2018 has fuelled the uncertainty, focused on fresh efforts to boost efficiency rather than any big deals.

"We are not thinking about asset disposal at this stage at all," he said after the trading update, adding that the company would concentrate on simplifying manufacturing, warehouse and distribution operations.

He remained tight-lipped when asked about Elliott.

"We do not comment on rumour or speculation and we don't comment on the identity of our investors unless required to do so under disclosure rules," he said.

The British company, which also has wound-care and sports medicine units, reported 3 percent revenue growth for the quarter, just shy of market forecasts, and nudged down its full-year guidance for revenue and trading margin growth to the lower end of its 3-4 percent and 20-70 basis point ranges.

'NOTHING STELLAR'

Berenberg analysts said the numbers were "nothing stellar" and largely in line with fairly low expectations.

Further detail on Bohuon's latest efficiency drive will be provided at the full-year results in February, he said.

Shares in the company hit a record high of 14.42 pounds last month and were up 0.8 percent at 13.94 pounds at 1038 GMT on Friday.

Berenberg, which has a hold rating on the stock, said the efficiency programme is unlikely to be a game changer.

"For the last decade the company has more or less been permanently engaged in such a programme and while we do believe that on each occasion the company achieved its cost-saving goals, margins and profit growth have not lived up to investor expectations," the broker said.

Smith & Nephew made revenue of $1.15 billion (£880 million) in the quarter, up 3 percent, against analyst expectations of about $1.16 billion.

Bohuon said market-beating growth from its knee implants and a recovery in emerging markets helped the company to meet the lower end of its growth target in the quarter.

Recent hurricanes in the United States, Mexico and Puerto Rico had about a $5 million impact, he added.

(Editing by David Goodman)

By Paul Sandle

Stocks treated in this article : Stryker Corporation, Smith & Nephew
Stocks mentioned in the article
ChangeLast1st jan.
SMITH & NEPHEW -0.32% 1325.5 Delayed Quote.3.26%
STRYKER CORPORATION -1.35% 173.74 Delayed Quote.13.74%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SMITH & NEPHEW
07/18ZIMMER BIOMET : Strategies For The $17 Billion Major Orthopedic Implants Market
AQ
07/10SMITH & NEPHEW : LCDCP Plate Hole of Smith & Nephew or Synthes or Zimmer
AQ
07/08SMITH & NEPHEW : Keimig, Hubka
AQ
07/04SMITH & NEPHEW : Timing of Smith & Nephew Second Quarter Trading and First Half ..
PU
06/29SMITH & NEPHEW : Proximal Femoral Locking Plate with Eight Corresponding Locking..
AQ
06/26SMITH & NEPHEW : 'Performance-led Procurement Why innovation should be front and..
AQ
06/25'PERFORMANCE-LED PROCUREMENT : Why innovation should be front and centre' says P..
AQ
06/22SMITH & NEPHEW : UK's NICE publishes a Medtech innovation briefing on PICO for t..
AQ
06/21“PERFORMANCE-LED PROCUREMENT : Why innovation should be front and centre&r..
PU
06/15SMITH & NEPHEW : Steadman Philippon Research Institute and Smith & Nephew Host F..
AQ
More news
News from SeekingAlpha
07/06Med devices group joins broad rally 
06/11Sell-siders weigh in on possible Boston Scientific - Stryker marriage 
05/29My IMF Portfolio's Top 30 Holdings (Part 1) 
05/14SMITH & NEPHEW : Not Attractive Enough 
05/04Smith & Nephew's (SNN) CEO Olivier Bohuon on Q1 2018 Results - Earnings Call .. 
Financials ($)
Sales 2018 5 009 M
EBIT 2018 1 002 M
Net income 2018 659 M
Debt 2018 1 102 M
Yield 2018 2,05%
P/E ratio 2018 22,18
P/E ratio 2019 18,93
EV / Sales 2018 3,30x
EV / Sales 2019 3,13x
Capitalization 15 438 M
Chart SMITH & NEPHEW
Duration : Period :
Smith & Nephew Technical Analysis Chart | SN. | GB0009223206 | 4-Traders
Technical analysis trends SMITH & NEPHEW
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 18,7 $
Spread / Average Target 7,5%
EPS Revisions
Managers
NameTitle
Namal Nawana Chief Executive Officer & Executive Director
Roberto Quarta Chairman
Matthew R. Stober President-Global Operations
Graham James Baker Chief Financial Officer & Director
Vasant Padmanabhan President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SMITH & NEPHEW3.26%15 438
STRYKER CORPORATION13.74%65 814
WRIGHT MEDICAL GROUP NV12.66%2 710
JAPAN LIFELINE CO., LTD.23.47%2 329
GLAUKOS CORP65.46%1 484
CERUS CORPORATION117.46%967